Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog(®) in Japanese patients with type 1 diabetes

Lignende værker

• Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis
  af: Jinnouchi, Hideaki, et al.
  Udgivet: (2020)
• Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog(®) in Japanese Patients with Type 1 Diabetes: PRONTO-T1D Subpopulation Analysis
  af: Miura, Junnosuke, et al.
  Udgivet: (2020)
• Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial
  af: Inoue, Megumi, et al.
  Udgivet: (2019)
• Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
  af: Home, Philip, et al.
  Udgivet: (2018)
• Insulin lispro (Humalog), the first marketed insulin analogue: indications, contraindications and need for further study.
  af: Puttagunta, A L, et al.
  Udgivet: (1998)